scispace - formally typeset
M

Min Zhou

Researcher at Shanghai Jiao Tong University

Publications -  5
Citations -  16305

Min Zhou is an academic researcher from Shanghai Jiao Tong University. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 1 publications receiving 12381 citations.

Papers
More filters
Journal ArticleDOI

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

TL;DR: Characteristics of patients who died were in line with the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia, and further investigation is needed to explore the applicability of the Mu LBSTA scores in predicting the risk of mortality in 2019-nCoV infection.
Journal ArticleDOI

Aetiology of severe community acquired pneumonia in adults identified by combined detection methods: a multi-centre prospective study in China

TL;DR: Early combined detection increased the pathogen identification rate and possibly benefitted survival in SCAP patients in China, and Physicians should be aware of the emergence of uncommon pathogens, including Chlamydia Psittaci and Leptospira.
Journal ArticleDOI

Automated interpretation of the pulmonary function test by a portable spirometer in Chinese adults

TL;DR: A portable spirometer is a promising alternative to a traditional pulmonary function test (PFT) spirometer for respiratory function evaluation.
Journal ArticleDOI

Stress hyperglycemia ratio is associated with systemic inflammation and clinical outcomes in diabetic inpatients with pneumonia on admission

TL;DR: In this article , the authors investigated the associations of stress hyperglycemia ratio with systemic inflammation and clinical outcomes in diabetic inpatients with pneumonia on admission, and found that SHR was associated with pneumonia.
Posted ContentDOI

Serum neutralization of SARS-CoV-2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld.

TL;DR: In this paper , the serum neutralization efficacy of Evusheld (cilgavimab and tixagevimab) against SARS-CoV-2 Omicron BA.